Last week we held the latest in our series of BIA member webinars, which focused on cell and gene therapy, with guest speakers Dr Sven Kili and Dr Emily Culme-Seymour from GSK, Michael Hunt of ReNeuron and Dr Damian Marshall from the Cell and Gene Therapy Catapult.

With emerging technologies and new clinical trials being developed and launched, the webinar examined just a few of the advances and evolution in the development of cell and gene therapies over the last couple of years, as well as business models and commercial milestones.

Joined by almost 100 participants on the webinar, BIA CEO Steve Bates noted the keen interest inspired by this sector.

Dr Sven Kili kicked things off with an introduction to the BIA’s Cell and Gene Therapy Advisory Committee, on which he holds the position of Chair. As a key area of focus for the BIA, the Committee’s expert input helps to inform BIA positions on relevant policy issues – such as the current Select Committee inquiry into Regenerative Medicine and, when it is published, the Accelerated Access Review.

Alongside the growing interest in cell and gene therapy witnessed in recent years, the area has also seen a growth in clinical development and likewise, investment. GSK is investing heavily in cell and gene therapy, and during the webinar Dr Emily Culme-Seymour outlined some of their ongoing projects of interest, including in GSK’s rare diseases portfolio. As for the future, the cell and gene therapy environment continues to evolve and Emily highlighted the benefits of utilising a more collaborative approach to the development of novel therapies, such as partnerships with SMEs and academia.

Next up was Michael Hunt, Chief Financial Officer of ReNeuron. Having been AIM-listed since 2005, Michael observed that the funding landscape has evolved over recent years. Michael gave an outline of ReNeuron’s therapeutic pipeline, covering treatments across the diverse areas of retinitis pigmentosa, motor disability from stroke, and critical limb ischaemia.

Finally, Dr Damian Marshall provided an overview of the Cell and Gene Therapy Catapult’s analytical platform for characterisation of cell therapy products, which allows data to be integrated from multiple platforms to analyse the biological, chemical and physical properties of cell products.

Watch the webinar in full below.